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Abstract
The neurotoxic amino acid, domoic acid (DA), is naturally produced by marine phytoplankton and presents a significant
threat to the health of marine mammals, seabirds and humans via transfer of the toxin through the foodweb. In humans,
acute exposure causes a neurotoxic illness known as amnesic shellfish poisoning characterized by seizures, memory loss,
coma and death. Regular monitoring for high DA levels in edible shellfish tissues has been effective in protecting human
consumers from acute DA exposure. However, chronic low-level DA exposure remains a concern, particularly in coastal and
tribal communities that subsistence harvest shellfish known to contain low levels of the toxin. Domoic acid exposure via
consumption of planktivorous fish also has a profound health impact on California sea lions (Zalophus californianus)
affecting hundreds of animals yearly. Due to increasing algal toxin exposure threats globally, there is a critical need for
reliable diagnostic tests for assessing chronic DA exposure in humans and wildlife. Here we report the discovery of a novel
DA-specific antibody response that is a signature of chronic low-level exposure identified initially in a zebrafish exposure
model and confirmed in naturally exposed wild sea lions. Additionally, we found that chronic exposure in zebrafish caused
increased neurologic sensitivity to DA, revealing that repetitive exposure to DA well below the threshold for acute
behavioral toxicity has underlying neurotoxic consequences. The discovery that chronic exposure to low levels of a small,
water-soluble single amino acid triggers a detectable antibody response is surprising and has profound implications for the
development of diagnostic tests for exposure to other pervasive environmental toxins.
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Introduction
Domoic acid (DA) is a small water-soluble marine algal toxin
that is naturally produced by diatoms of the genus Pseudo-nitzschia
during harmful algal blooms (HABs) [1]. In humans, acute
exposure causes a neurotoxic illness known as amnesic shellfish
poisoning (ASP) that is characterized by gastrointestinal distress,
seizures, confusion, memory loss, coma and death in the most
severe cases [2]. The first documented cases of ASP occurred in
Eastern Canada in 1987 when over 100 people became ill and 3
died as a result of consuming DA contaminated mussels [3]. Since
that event, consistent monitoring of shellfish beds for the presence
of DA in edible shellfish tissues ($20 mg DA/g shellfish=regula-
tory limit) has been effective in protecting human consumers from
acute DA exposure [4]. However, there are growing concerns
about the impacts of low-level repetitive exposure, particularly in
coastal and tribal communities that rely heavily on the harvests of
local shellfish with known low levels of the toxin [5]. In addition to
human health concerns, DA exposure via consumption of
planktivorous fish has a significant impact on California sea lions
along the US West Coast resulting in the stranding and/or deaths
of hundreds of animals yearly [6,7]. These naturally exposed sea
lions represent a valuable ‘‘sentinel’’ species for human health risks
as related to DA exposure. Recently, two syndromes of DA
toxicosis have been identified in sea lions, an acute syndrome and
a chronic syndrome [8]. The chronic syndrome has been observed
in stranded sea lions even in the absence of DA producing algal
blooms in the environment, suggesting that sub-lethal DA
exposure leads to lasting neurologic effects in mammalian species
[8].
In light of the recognized increase in frequency and geographic
range of HABs globally [9], there is a critical need for reliable
diagnostic tests for assessing chronic HAB toxin exposure in
coastal human populations and wildlife. To date, most suspected
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post mortem histologic examination of brain tissue, and examining
bodily fluids, stomach contents and/or feces for the presence of the
toxin [6,7,10,11]. None of these methods are effective for
accurately assessing chronic low-level exposure and the associated
sub-acute neurotoxic effects, which are the main human health
related concerns [12]. For example, behavioral symptoms typically
represent high-level exposures and examination of brain tissues for
damage is possible only after death or with expensive MRI
techniques in live animals [13]. Additionally, systemic toxin levels
are not reliable indicators of exposure because DA is rapidly
depurated, with 99% of circulating DA levels excreted within
4 hours in experimentally injected primates [14]. Therefore toxin
levels or lack thereof are not indicative of exposure levels or
history. The lack of a diagnostic biomarker for chronic DA
exposure presents a significant barrier to properly characterizing
exposure and health risk, because without the ability to assess
exposure, there is no way to accurately determine health and
disease impacts related to chronic exposure.
In the present study, zebrafish were used as a vertebrate model
species to identify potential health risks and associated biomarkers
of chronic low level DA exposure applicable to human and marine
mammal populations. Chronic low-level exposure to DA induced
an antibody response and increased toxin sensitivity. Historically,
specific antibody responses have been generated in other
vertebrate species against small haptens that are similar in size
to DA when coupled to serum proteins for immunogenicity [15].
Importantly, the putative antibody response in zebrafish was
further validated in field exposed California sea lions. Thus we
demonstrate that this antibody response is an ecologically relevant
biomarker of chronic exposure and increased neurologic sensitivity
that may be useful for assessing DA related sublethal pathology in
both marine mammal and human populations.
Methods
Chronic Exposures in Zebrafish
Wild-type zebrafish (Danio rerio, AB strain) were obtained from
Oregon State University, Sinnhuber Aquatic Research Laboratory
(Corvallis, OR) at approximately 5 months of age and maintained
at the Northwest Fisheries Science Center (NWFSC) in a ZebTec
stand-alone recirculating and continuously monitored zebrafish
rack system with UV sterilizer (Techniplast, Exton, PA). Fish were
maintained at 26uC, kept on a 12:12 hr light:dark cycle, and fed
daily with commercially available fish feed. At approximately 7
months of age, zebrafish were repetitively exposed to asymptom-
atic doses of DA via intracoelomic (IC) injection for 36 weeks,
followed by a seven-week recovery period. Blood serum (n=9
control, n=9 exposed) and whole brains (n=9 control, n=9
exposed) were collected from zebrafish at 12 time points (6, 24 and
48 hours, and 1, 2, 6, 12, 18, 24 and 36 weeks of exposure and 3
and 7 weeks of recovery) throughout the experiment for DA
quantification in serum and whole brain transcriptome analyses
via microarray. Toxin and vehicle (PBS) injections were given
once a week (dose=0.3160.03 mg DA/g fish) for the first 6 weeks,
then once every two weeks (dose=0.1860.02 mg DA/g fish) for
the duration of the exposure period of 36 weeks. Doses of less than
half of the previously reported EC50 (0.86 mg DA/g fish) for
zebrafish [16] were chosen to ensure asymptomatic exposures. All
toxin dose concentrations were verified via HPLC as described in
Lefebvre et al. (2009) [16]. Domoic acid injections were performed
as described in Lefebvre et al. (2009) [16].
Zebrafish Serum Collection and Analyses
For serum collection at all 12 time points, zebrafish (n=9
control and n=9 exposed) were individually netted and placed in
an ice bath until quiescent. The tail was then cut posterior to the
anal fin and blood was collected from the caudal vein using a
heparinized 44.7 ml microcapillary tube (Drummond Scientific
Company, Broomall, PA). Tubes were sealed at one end with clay
and spun in a hematocrit centrifuge for one minute to separate
plasma from red blood cells. Tubes were scored at the interface
between plasma and red blood cells and the plasma was collected
in a microfuge tube and stored at -20uC until analysis.
Domoic acid was quantified in three serum replicates (each
consisting of 3 pooled zebrafish serum samples) using a
commercially available competitive ELISA kit (BiosenseH). DA
values were quantified following the kit guidelines at the following
time points; 6, 24, and 48 hours, and 1, 2, 6, 12, 18, 24 and 36
weeks of exposure, and at 3 and 7 weeks after the last injection
(recovery time points). It was later discovered that although the
commercial kit was designed and advertized for DA quantification
exclusively, the competitive ELISA format detects the presence of
both DA and DA-specific antibodies indiscriminately in serum (see
results section).
Brain Dissections and RNA Extraction
Brains were dissected as described in Lefebvre et al. (2009) [16].
Global transcriptome expression was quantified via microarray in
three RNA replicates (each consisting of RNA from 3 pooled
brains) for exposed and control treatments. Test group size was
chosen based on a previous study in which the appropriate
number of zebrafish brains required to obtain sufficient quantities
of high quality RNA for microarray analysis was determined [16].
Total RNA was isolated from zebrafish brains (n=9 for each
treatment and time point) using the miRNeasy Mini Kit (Qiagen
Inc., Valencia, CA) according to the vendor’s defined method, and
stored at 270uC. The quantity (ng/uL) of RNA was determined
measuring the OD260 with a NanoDrop ND-1000 Spectropho-
tometer (Thermo Fisher Scientific, Waltham, MA) and the RNA
purity was assessed measuring OD260/280 and OD260/230 ratios.
RNA integrity (quality) was characterized using the Agilent RNA
6000 Nano Kit with an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA). Only total RNA samples with
appropriate size distribution, quantity, and A260:A280 as well as
A260:A230 ratios of 1.8–2.1 were used for microarray-based
analysis. Individual brain RNA samples were split and half used
for microarray analyses and half used for RT-PCR confirmation.
Global Transcriptome Profiling in Brain
The RNA samples were labeled and prepared for hybridization
onto a Zebrafish (V3) Gene Expression Microarray (Agilent
Technologies, Inc. Santa Clara, CA) using the manufacturer’s
established protocols. Hybridization and washing of these arrays
was accomplished using HS 400 Pro hybridization and wash
stations (Tecan Systems, Inc., San Jose, CA) and scanned using an
Agilent DNA Microarray Scanner (Agilent Technologies, Inc.
Santa Clara, CA) using previously established methods. In total,
72 microarrays were used, including 36 for the control group and
36 for the chronic exposure group. Separate pools of RNA from
three individuals were hybridized to each array resulting in three
biological replicates (a total of nine individuals) per treatment
group and time point.
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Raw microarray data was generated with the Agilent Feature
Extraction image analysis software (Agilent). Raw microarray data
were further processed and analyzed with tools from Bioconductor
[17]. Data were normalized using the BioconductorAgi4644Pre-
Process package [18]. Additionally, the normexp option for
background adjustment and quantile normalization was used for
the between array normalization step. Using the normalized data,
we identified genes with significant evidence for differential
expression using the limma package. The limma methodology
calculates a P-value for each gene using a modified t-test in
conjunction with an empirical Bayes method to moderate the
standard errors of the estimated log-fold changes. This method of
detecting differentially expressed genes draws strength across genes
for more robust and accurate detection of differentially expressed
genes. Such an adjustment has repeatedly been shown to avoid an
excess of false positives when identifying differentially expressed
genes [19]. Using the P-values from limma, we used the
Bioconductor package p.adjust [20] to estimate the false discovery
rate associated with our list of differentially expressed genes. This
methodology allows us to address the multiple testing problem
without resorting to an excessively conservative approach that
controls the familywise error, such as a Bonferroni correction. In
addition, we used the Bioconductor kmeans [21] function from the
stats package to perform K-means clustering of the genes. In order
to identify Gene Ontology categories that were enriched with the
differentially expressed genes, we used the functional annotation
clustering tool available through NIAD DAVID (http://david.
abcc.ncifcrf.gov/) [22].
Quantitative RT-PCR Analyses
Four immune-relevant genes displaying significant upregulation
by microarray analyses at 18 weeks in the K-means cluster shown
in Figure 1B were further validated by RT-PCR at four time
points (6, 12, 18, and 24 weeks). Total RNA was isolated from
individual zebrafish brains (n=9 control and n=9 chronic at four
time points as described above). RT-PCR was performed on
individual samples. Briefly, reverse transcription was performed
according to the manufacturer’s established protocol using total
RNA and the SuperScriptH III First-Strand Synthesis System
(Invitrogen, Carlsbad, CA.). For gene expression measurements,
2 mL of cDNA were included in a PCR reaction (12 mL final
volume) that consisted of the ABI inventoried TaqManH Gene
Expression Assays mix (Applied Biosystems Inc., Foster City, CA),
or customized forward and reverse primers, probes and TaqMan
Gene Expression Master Mix (Applied Biosystems Inc., Foster
City, CA). The PCR primers and the dual-labeled probes for the
genes were designed using ABI Primer Express v.1.5 software
(Applied Biosystems Inc., Foster City, CA). Amplification and
detection of PCR amplicons were performed with the ABI PRISM
7900 system (Applied Biosystems Inc., Foster City, CA) with the
following PCR reaction profile: 1 cycle of 95uC for 10 min, 40
cycles of 95uC for 30 sec, and 60uC for 1 min. Beta-actin 1
amplification plots derived from serial dilutions of an established
reference sample were used to create a linear regression formula in
order to calculate expression levels, and Beta-actin 1 gene
expression levels were utilized as an internal control to normalize
the data.
Dose Response Assays to Assess Neurologic Sensitivity
In order to quantify the impact of chronic exposure on
neurologic sensitivity, a second chronic exposure experiment was
performed in zebrafish for 20 weeks under the same chronic low-
level exposure conditions as described for the first experiment. At
20 weeks, chronically exposed zebrafish and control zebrafish were
subjected to a dose response bioassay. Dose response assays were
performed and ED50 calculations made as described in Lefebvre et
al. (2009) [16] with the exception that five DA doses and a PBS
control dose were used in the present study. Spiral swimming was
used as the behavioral metric to determine acute neurotoxicity. All
doses were validated using HPLC [16].
Indirect ELISAs for Domoic acid-Specific Antibody
Detection in Sea Lion Serum
Sea lion serum samples from 17 naturally exposed animals
admitted to The Marine Mammal Center were analyzed for the
presence of a DA-specific IgG antibody via an indirect ELISA
(Table 1). Additionally, five control serum samples were obtained
from healthy sea lions born and raised in captivity at Sealife Park
Hawaii for method validation. Detection specificity of DA-specific
sea lion IgG was accomplished using a DA conjugated 96-well
plate. Serum was applied to sample wells and DA-specific
antibodies allowed to bind to the DA conjugated to the plate.
After thorough washing, HRP labeled anti-canine IgG was
allowed to incubate, TMB substrate was added, and absorbance
was detected with a Bio Tek Epoch Plate reader. The indirect
format of this ELISA detects DA specific antibodies exclusively
and is not subject to ‘‘false positive’’ interference by the presence of
DA.
Results
Zebrafish Serum Analyses via BiosenseH Competitive
ELISAs
Serum DA values as quantified via BiosenseH ELISA in control
and exposed zebrafish are depicted in Figure 1A. The first time
points (6 hrs, 24 hrs, 48 hrs and 1 week) represent a depuration
curve for DA in blood serum after the first injection for the study.
Serum samples for time points 2 through 36 weeks were all taken
one week after the most recent DA injection. The final two data
points to the right of the dashed line represent recovery time points
(3 and 7 weeks after the last DA injection). In spite of the fact that
DA doses and dosing frequency decreased after 6 weeks, toxin
values in serum as quantified via BiosenseH ELISA increased.
Additionally, these values remained high throughout the recovery
period up to 7 weeks after the last DA injection (Figure 1A).
Further examination of the ‘‘competitive’’ ELISA format revealed
that the commercial assay detects both DA and DA-specific
antibodies. The fact that DA is highly water soluble and rapidly
excreted, led us to interpret that the increase in DA signal after 18
weeks and into recovery was likely due to the presence of a DA-
specific antibody and not an indication of increased serum DA
levels (Figure 1). For example, a DA specific antibody (IgM)
present in zebrafish serum would bind to DA conjugated to the
ELISA plate and compete with the BiosenseH labeled detection
antibody, resulting in a decrease in absorbance just as DA in a
sample competes with the labeled antibody in solution, also
causing decreased absorbance. These data provided the first
indication that chronic low-level DA exposure elicits a detectable
antibody response in the zebrafish model even in the absence of
overt neurobehavioral excitotoxicity.
Whole Brain Transcriptome Analyses in Zebrafish
Data from whole brain transcriptome analyses provided further
evidence for the induction of a significant immune response at the
later chronic exposure time points. K-means clustering of all
significantly differentially expressed genes (1.5 fold; p,0.05) in
whole brains taken from zebrafish at all time points identified a
Novel Biomarker for Chronic Algal Toxin Exposure
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david.abcc.ncifcrf.gov/; enrichment score: 1.98) that were signif-
icantly upregulated at 18 weeks, just before the apparent increase
in DA specific antibody titer in serum (Figure 1B). Gene Ontology
(GO) terms for Biological Process represented in the annotation
clusters included ‘‘antigen processing and presentation’’, ‘‘MHC
protein complex’’ and ‘‘immune response’’.
RT-PCR Confirmation of Significantly Differentiated
Genes
Four immune-relevant genes (CC chemokine (CCL19-like),
MHC class IIA and B, and an MHC class I gene) displaying
significant upregulation by microarray analyses and present in the
K-means cluster shown in Figure 1B were further validated by
Figure 1. A) Response of BiosenseH (Bergen, Norway) competitive enzyme-linked immunosorbent assays (ELISAs) in serum of
exposed and time-matched control zebrafish (Danio rerio) at all sampling time points. Detection by competitive ELISA indicates the
presence of DA and/or DA-specific antibodies in serum. B) One K-means cluster for a set of significantly differentially expressed genes (1.5 fold;
p,0.05) quantified in whole brains from exposed and control zebrafish. The y-axis represents the log2 fold-change for genes in this cluster at all
sampling time points (x-axis). The K-means algorithm forces all differentially expressed genes into clusters or groups with other genes that behave
most similarly over all time points. Once clusters have been formed, further analysis of the known functions of the genes within each cluster can be
used to identify potentially impacted biological processes. Functional annotation clustering using DAVID (http://david.abcc.ncifcrf.gov/) of the genes
shown here identified Immune Function as the major functional group (enrichment score: 1.98). Up regulation of immune related genes at 18-weeks
(demarked by *) indicates a significant immune response, after which antibody levels appear to rise in the blood (Figure 1A).
doi:10.1371/journal.pone.0036213.g001
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and 24 weeks). For the 16 contrasts (four genes at four time points),
14 agreed in fold change direction while two were too small in
magnitude for reliable comparisons.
Dose Response Analyses and Neurologic Sensitivity
Dose response curves for chronically exposed zebrafish and
naively exposed zebrafish are shown in Figure 2. The 50%
effective dose (ED50) is calculated from the dose response
relationship as the dose that effects 50% of the test population
and is used as a metric for comparing toxin sensitivities. Resulting
ED50s of 0.43 and 1.23 mg DA/g for chronic and naive
populations, respectively, indicated that chronically exposed
zebrafish were three times more sensitive to DA than naively
exposed zebrafish.
Antibody Detection in Sea Lion Serum via Indirect ELISAs
Eleven of 17 wild sea lions admitted to The Marine Mammal
Center had detectable levels of DA-specific antibodies in serum,
thereby verifying the presence of the proposed biomarker in a
naturally exposed mammalian species. Five control sea lion serum
samples from captive animals yielded a mean absorbance value of
0.05160.002 (SD). An additional blank (n=6) using sample buffer
only (no serum) yielded a mean absorbance value of 0.04960.002
(SD). Together these data confirmed that non-specific binding of
sea lion IgG in control serum did not occur in this assay format.
Table 1. Confirmation of the presence of a domoic acid (DA)-specific antibody in naturally exposed California sea lion (Zalophus
californianus) serum samples as detected via an indirect enzyme-linked immunosorbent assay (ELISA).
CSL-ID # Absorbance Ratio Seizures (yes/no) Admit Date Serum Collection Day
a
W-9759 9.88 Yes 7/10/10 1
W-9864 7.59 Yes 10/11/10 0
W-9876 2.85 Yes 10/16/10 1
W-10047 1.72 Yes 8/11/11 1
W-6920 1.51 No 6/30/06 1
W-7923 1.27 No 11/10/08 49
W-10046 1.23 Yes 8/11/11 1
W-6990 1.23 No 10/16/06 7
W-10035 1.16 Yes 8/5/11 2
W-10045 1.12 Yes 8/10/11 1
W-10044 1.11 Yes 8/10/11 1
W-9114 nd Yes 10/7/09 18
W-8739 nd Yes 7/21/09 4
W-10026 nd Yes 8/5/11 3
W-8032 nd No 1/16/09 32
W-6980 nd No 8/15/06 3
W-7899 nd No 10/15/08 35
C- 1 nd No na na
C- 2 nd No na na
C- 3 nd No na na
C- 4 nd No na na
C- 5 nd No na na
CSL=California sea lion; W=Wild; C=control healthy animals born and raised in captivity at Sealife Park Hawaii with presumably no history of domoic acid exposure;
Absorbance Ratio=sample serum absorbance4(mean control serum absorbance+3SD); Values .1 indicate presence of DA-specific antibody; nd=not detectable;
na=not applicable;
aNumber of days after admission to the Marine Mammal Center before serum was collected.
doi:10.1371/journal.pone.0036213.t001
Figure 2. Dose-response relationship between intracoelomic
(IC) injection doses of domoic acid (DA) and the percentage of
zebrafish affected (n=4 at each dose) for chronically exposed
(red line) and control (green line) zebrafish. Circular and/or spiral-
swimming behaviors were used to quantify excitotoxicity in fish. The
50% Effective Dose (ED50)=the dose at which 50% of the fish tested
were affected (mg DA/g). The dose-response experiment was carried out
at 20 weeks of exposure (one week after the last injection).
doi:10.1371/journal.pone.0036213.g002
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specific antibodies (Table 1). Absorbance ratios were calculated by
dividing the wild serum sample absorbance (X) by the mean
control serum absorbance plus three times SD (X/0.057).
Discussion
Together our data revealed that chronic low-level exposure to
DA induces a detectable antibody response and has underlying
neurotoxic consequences. The sub-acute repetitive dosing regime
in the zebrafish provided a vertebrate model that identified a
diagnostic biomarker of chronic exposure that was further verified
in a naturally exposed mammalian human health sentinel species,
the California sea lion.
At the transcriptional level, whole-genome microarray profiling
provided evidence of a significant immune response in the
zebrafish model that was temporally linked to the proposed
antibody response (Figure 1). Gene Ontology (GO) terms for
Biological Process represented in the annotation clusters included
‘‘antigen processing and presentation’’, ‘‘MHC protein complex’’
and ‘‘immune response’’, all of which are suggestive of an
activated immune system. Four immune-relevant genes from this
cluster displaying significant upregulation by microarray analyses
were further validated by RT-PCR; CC chemokine (CCL19-like),
MHC class IIA and B, and an MHC class I gene. The altered
expression of these genes is likely derived from chronically
activated microglia, the resident macrophages of the brain,
resulting in enhanced proinflammatory responses, chemotaxis,
and antigen presentation in the brain [23,24]. Chemokines are
small, secreted proteins that function in leukocyte trafficking and
activation but are also associated with inflammatory and
pathological processes [25] as might be expected from chronic
DA exposure (e.g. neuronal degeneration). Additionally, upregula-
tion of MHC class I and II genes implies enhanced antigen
presentation of non-self to cytotoxic and helper T-cells, respec-
tively. Taken together, the induction of these and other immune-
relevant genes implies that chronic DA exposure results in immune
activation. It is unlikely that DA alone would result in lymphocyte
activation, but when coupled to carrier proteins in serum or on
cells, it could modify self-proteins and thus act as a potent hapten
for stimulating both B and T cell mediated responses including
specific antibody production. Hapten modified self-proteins have
been shown to elicit antibody production and T cell effector
function [26,27,28,29]. Specifically, a potential mechanism for DA
mediated humoral responses observed in this study could include
DA modification of self through reactive carbonyl groups on DA
as shown for other small haptens [30].
In addition to a DA specific immune response, chronic low-level
DA exposure had quantifiable neurologic consequences on whole
animal health. In dose response experiments, chronically exposed
zebrafish were three times more sensitive to DA than naively
exposed zebrafish (ED50s of 0.43 and 1.23 mg DA/g for
chronically-exposed and naive populations, respectively), revealing
that repetitive low-level exposure increases neurologic sensitivity to
the toxin in subsequent exposures (Figure 2). This increased toxin
sensitivity has profound health implications for human populations
that regularly consume shellfish containing low levels of DA as well
as for repetitively exposed sea lions. The results suggest that long-
term low-level exposure does not result in tolerance or resistance
but actually increases the health risks associated with subsequent
exposures. This finding and its linkage to a detectable DA specific
antibody response provide a valuable example of a diagnostic test
specific for chronic low-level exposure that is linked to a subclinical
neurotoxic health condition.
Further testing in wild naturally-exposed California sea lions
confirmed that the proposed DA specific antibody response
identified in zebrafish is a potential biomarker for chronic DA
exposure in natural ‘‘at risk’’ populations. Utilizing an anti-canine
IgG antibody that cross-reacts with sea lion IgG [31] and a DA-
conjugated plate, we developed an indirect ELISA that exclusively
detects DA-specific antibodies in sea lion serum without
interference by DA. The presence of DA specific antibodies was
confirmed in 65% of the sea lion serum samples analyzed (n=11
of 17; Table 1). Veterinarians frequently use the presence of
seizures to diagnose symptomatic DA toxicosis, once other
common causes of seizures such as trauma, infections and
metabolic imbalances have been ruled out [7]. Based on data
from the zebrafish model, repetitive exposure over time is required
for induction of a DA specific antibody response (Figure 1A). This
indicates that the presence of antibodies selectively identifies
chronically exposed animals and that antibodies may not be
present in naive animals or those without sufficient repetitive
exposure. In our sea lion data set, three animals (W-6920, 7923,
and 6990) had detectable DA-specific antibody titers, but had not
exhibited clinical signs of DA-induced excitotoxicity (e.g. seizures),
suggesting a chronic exposure history, but no recent acute
exposure. Conversely, three other animals (W-9114, 8739, and
10026) exhibited DA-related seizures, but did not have measurable
quantities of DA-specific antibodies (Table 1), suggesting that these
animals had been acutely exposed based on clinical signs of
toxicity but potentially not chronically exposed based on lack of
detection of the antibody biomarker. The distinction of ‘‘chronic’’
exposure for sea lion health assessments is critical for prescribing
proper treatments as chronically exposed animals have different
health changes and expected recovery outcomes than acutely
exposed sea lions [8]. In the case of ‘‘at risk’’ human populations, it
is chronic low-level exposure that presents the most significant
health risk and the absence of a biomarker for exposure has been a
barrier to accurately assessing the health and disease impacts
related to chronic exposure in these populations [12].
Conclusions
Collectively, our data provide strong evidence for the
production of a specific antibody response induced by repetitive
low-level exposure to a pervasive algal toxin. The resulting
antibody response fills a critical need for a quantifiable biomarker
for chronic exposure that would be useful for wildlife as well as
human health assessments. The next steps are to validate this
finding in human populations, particularly those with regular
exposure to low levels of DA. Several coastal and tribal
communities in the Pacific Northwest region of the U.S. rely
heavily on razor clams as a food source, a species known to
accumulate DA and retain the toxin for long periods [32]. The
biomarker discovered here identifies chronic exposure exclusively
and not acute one time exposure. This type of biomarker is
critically important for human health assessments of pervasive
environmental toxins, especially in light of our finding that chronic
exposure increases toxin sensitivity, thereby making organisms
more susceptible to DA toxicity in subsequent exposures. This
comprehensive chronic exposure study, leading from the identi-
fication of an antibody-based biomarker in a laboratory fish model
to field verification of the biomarker in naturally exposed
mammals provides a new paradigm for chronic exposure
assessment that can be applied to other pervasive environmental
toxins.
Novel Biomarker for Chronic Algal Toxin Exposure
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